Literature DB >> 15229056

Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV.

Marta Torrens1, Domènec Serrano, Mònica Astals, Gustavo Pérez-Domínguez, Rocío Martín-Santos.   

Abstract

OBJECTIVE: The authors' goal was to assess the validity of DSM-IV diagnoses obtained with the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders (PRISM) and the Structured Clinical Interview for DSM-IV (SCID) compared with the longitudinal, expert, all data (LEAD) procedure in a group of substance abusers.
METHOD: A total of 105 substance abusers recruited at a drug abuse treatment center in Barcelona, Spain, were assessed. The PRISM and SCID were administered blindly by independent research interviewers. LEAD diagnoses were made by two senior psychiatrists who were blind to PRISM and SCID diagnoses. The kappa statistic was used to measure concordance between the LEAD procedure and the PRISM and SCID.
RESULTS: Affective and anxiety disorders were diagnosed more frequently by the PRISM and SCID than by the LEAD procedure. Use of the PRISM resulted in more diagnoses of substance-induced depression, and use of the SCID resulted in more diagnoses of primary major depression than the LEAD procedure. Kappas between the LEAD procedure and the PRISM in current major depression, past substance-induced depression, and borderline personality disorder were better than those obtained between the LEAD procedure and the SCID. The concordance among the three methods for diagnoses of current dependence disorders was good or excellent for alcohol, anxiolytic, cocaine, and heroin dependence and fair for cannabis dependence. Abuse diagnoses showed poor concordance.
CONCLUSIONS: Using the LEAD procedure as a "gold standard," the authors conclude that the Spanish version of the PRISM seems to be a better instrument than the Spanish version of the SCID for diagnosing major depression and borderline personality disorders in substance abusers.

Entities:  

Mesh:

Year:  2004        PMID: 15229056     DOI: 10.1176/appi.ajp.161.7.1231

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  58 in total

1.  Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Analucía A Alegría; Deborah S Hasin; Edward V Nunes; Shang-Min Liu; Carrie Davies; Bridget F Grant; Carlos Blanco
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

2.  Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence.

Authors:  Sharon Samet; Miriam C Fenton; Edward Nunes; Eliana Greenstein; Efrat Aharonovich; Deborah Hasin
Journal:  Addiction       Date:  2012-10-05       Impact factor: 6.526

3.  Procedural validity of the AUDADIS-5 depression, anxiety and post-traumatic stress disorder modules: Substance abusers and others in the general population.

Authors:  Deborah S Hasin; Dvora Shmulewitz; Malka Stohl; Eliana Greenstein; Christina Aivadyan; Kara Morita; Tulshi Saha; Efrat Aharonovich; Jeesun Jung; Haitao Zhang; Edward V Nunes; Bridget F Grant
Journal:  Drug Alcohol Depend       Date:  2015-04-06       Impact factor: 4.492

4.  Predictors of psychosis remission in psychotic disorders that co-occur with substance use.

Authors:  Carol L M Caton; Deborah S Hasin; Patrick E Shrout; Robert E Drake; Boanerges Dominguez; Sharon Samet; Bella Schanzer
Journal:  Schizophr Bull       Date:  2006-07-27       Impact factor: 9.306

5.  Subtyping patients with heroin addiction at treatment entry: factor derived from the Self-Report Symptom Inventory (SCL-90).

Authors:  Icro Maremmani; Pier Paolo Pani; Matteo Pacini; Jacopo V Bizzarri; Emanuela Trogu; Angelo Gi Maremmani; Gilberto Gerra; Giulio Perugi; Liliana Dell'Osso
Journal:  Ann Gen Psychiatry       Date:  2010-04-13       Impact factor: 3.455

6.  COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users.

Authors:  Antonio Verdejo-García; Ana Beatriz Fagundo; Aida Cuenca; Joan Rodriguez; Elisabet Cuyás; Klaus Langohr; Susana de Sola Llopis; Ester Civit; Magí Farré; Jordi Peña-Casanova; Rafael de la Torre
Journal:  Neuropsychopharmacology       Date:  2013-02-28       Impact factor: 7.853

7.  Predictors of dropout in concurrent treatment of posttraumatic stress disorder and alcohol dependence: Rate of improvement matters.

Authors:  Laurie J Zandberg; David Rosenfield; Elizabeth Alpert; Carmen P McLean; Edna B Foa
Journal:  Behav Res Ther       Date:  2016-03-03

Review 8.  Assessing addiction: concepts and instruments.

Authors:  Sharon Samet; Rachel Waxman; Mark Hatzenbuehler; Deborah S Hasin
Journal:  Addict Sci Clin Pract       Date:  2007-12

9.  Screening for personality disorder with the Standardised Assessment of Personality: Abbreviated Scale (SAPAS): further evidence of concurrent validity.

Authors:  Morten Hesse; Paul Moran
Journal:  BMC Psychiatry       Date:  2010-01-28       Impact factor: 3.630

10.  Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study.

Authors:  Mònica Astals; Laura Díaz; Antònia Domingo-Salvany; Rocío Martín-Santos; Antoni Bulbena; Marta Torrens
Journal:  Int J Environ Res Public Health       Date:  2009-11-12       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.